The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I trial of VB-111, a tissue- and condition-specific dual action vascular disruptive and antiangiogenic agent, for treatment of patients with advanced metastatic cancer.
A. J. Brenner
Consultant or Advisory Role - VBL Therapeutics
Research Funding - VBL Therapeutics
Y. Cohen
Employment or Leadership Position - VBL Therapeutics
F. J. Giles
Research Funding - VBL Therapeutics
E. C. Borden
Consultant or Advisory Role - VBL Therapeutics (U)
Research Funding - VBL Therapeutics
E. Breitbart
Employment or Leadership Position - VBL Therapeutics
L. Bangio
Employment or Leadership Position - VBL Therapeutics
N. Sher
Employment or Leadership Position - VBL Therapeutics (U)
P. L. Triozzi
Research Funding - VBL Therapeutics